<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006230</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16996O</org_study_id>
    <secondary_id>EORTC-16996O</secondary_id>
    <nct_id>NCT00006230</nct_id>
  </id_info>
  <brief_title>Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer</brief_title>
  <official_title>Open Label Phase II Study on RFS 2000 (9-Nitro-camptothecin, 9-NC) Administered as a &quot;5 Days On-2 Days Off&quot; Oral Treatment in Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients&#xD;
      who have advanced ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate and duration of response in patients with advanced&#xD;
           ovarian cancer treated with nitrocamptothecin.&#xD;
&#xD;
        -  Determine the probability of objective response as expressed by the response rate in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to disease status&#xD;
      (sensitive vs refractory).&#xD;
&#xD;
      Patients receive oral nitrocamptothecin daily for 5 consecutive days each week for 3 weeks.&#xD;
      Treatment continues every 3 weeks for a minimum of 2 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients who achieve stable disease (SD) receive up to&#xD;
      4 additional courses past SD. Patients who achieve partial response (PR) or complete response&#xD;
      (CR) receive a minimum of 2 additional courses past PR or CR.&#xD;
&#xD;
      Patients are followed every 6 weeks until disease progression or the initiation of another&#xD;
      antitumor therapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28-50 patients (14-25 per stratum) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">51</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rubitecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven metastatic or unresectable locally advanced progressive ovarian&#xD;
             cancer that has failed first line platinum and taxane based regimen&#xD;
&#xD;
               -  Refractory disease defined by a relapse within 1 year after completion of first&#xD;
                  line therapy&#xD;
&#xD;
               -  Sensitive disease defined by a relapse greater than 1 year after completion of&#xD;
                  first line therapy&#xD;
&#xD;
          -  Minimum of 1 target lesion that can be accurately measured in at least 1 dimension&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase, SGOT, and SGPT no greater than 2.5 times ULN (no greater than 5&#xD;
             times ULN if hepatic metastases present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.7 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No ischemic heart disease within the past 6 months&#xD;
&#xD;
          -  Normal 12 lead electrocardiogram&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No unstable systemic disease or active uncontrolled infections&#xD;
&#xD;
          -  No other prior or concurrent malignancy except adequately treated basal cell or&#xD;
             squamous cell skin cancer or cone biopsied carcinoma of the cervix&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) with nitrocamptothecin&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Greater than 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Greater than 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Greater than 2 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Fumoleau, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Georges Francois Leclerc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer, Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Campus</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova (Padua)</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique De Genolier</name>
      <address>
        <city>Genolier</city>
        <zip>Ch-1272</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle General Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rubitecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

